iRadimed Corporation $IRMD Stock Holdings Cut by Vanguard Group Inc.

Vanguard Group Inc. reduced its position in shares of iRadimed Corporation (NASDAQ:IRMD) by 1.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 560,048 shares of the medical equipment provider’s stock after selling 6,459 shares during the period. Vanguard Group Inc.’s holdings in iRadimed were worth $54,481,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its stake in iRadimed by 827.1% during the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 397 shares in the last quarter. CWM LLC boosted its stake in iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 211 shares in the last quarter. Quarry LP bought a new position in iRadimed during the 3rd quarter valued at $40,000. State of Alaska Department of Revenue bought a new position in iRadimed during the 3rd quarter valued at $47,000. Finally, Tower Research Capital LLC TRC boosted its stake in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 495 shares in the last quarter. 92.34% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Lake Street Capital reaffirmed a “buy” rating and set a $120.00 price target on shares of iRadimed in a research note on Wednesday, February 11th. Roth Mkm reaffirmed a “buy” rating and set a $120.00 price target on shares of iRadimed in a research note on Tuesday, February 10th. Weiss Ratings raised iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, May 6th. Finally, Freedom Capital raised iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $120.00.

iRadimed Stock Down 0.5%

IRMD opened at $86.44 on Friday. The firm has a market cap of $1.10 billion, a PE ratio of 47.24 and a beta of 0.90. The business has a fifty day simple moving average of $93.68 and a 200-day simple moving average of $94.67. iRadimed Corporation has a fifty-two week low of $50.88 and a fifty-two week high of $107.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.03. The business had revenue of $21.98 million during the quarter, compared to analyst estimates of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, equities research analysts anticipate that iRadimed Corporation will post 1.52 EPS for the current fiscal year.

iRadimed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 15th will be paid a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is currently 43.72%.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 4,411 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $83.92, for a total transaction of $370,171.12. Following the completion of the sale, the chief executive officer directly owned 2,180,000 shares of the company’s stock, valued at $182,945,600. This trade represents a 0.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 60,000 shares of company stock worth $5,661,603. Company insiders own 36.80% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.